These data suggested that combined ILT4 and PD-L1 blockade synergistically prevented recruitment and M2-like polarization of TAMs in both EGFR-TKI resistant and EGFR wild-type NSCLC and might cooperate to repress TAM-mediated tumor promotion. The gene discussed is LILRB2; the disease is neoplasm.